Business Wire

Ferring Pharmaceuticals appoints new Executive Chairman among key changes to Board of Directors

Share

Ferring Pharmaceuticals announced today that Jean-Frédéric Paulsen has been appointed Executive Chairman of the Ferring Group, as it enters a new phase of growth following the approval of two innovative medicines by the US Food and Drug Administration.

Mr. Paulsen, who joined Ferring’s Board of Directors1 in July 2021, played a leading role in securing the US approval of Adstiladrin® (nadofaragene firadenovec-vncg), a first-in-class gene therapy offering a new approach to treating a severe form of BCG-unresponsive non-muscle invasive bladder cancer. Another breakthrough for the company came with the US approval of Rebyota™ (fecal microbiota – live jslm), the first FDA-approved microbiota-based live biotherapeutic, for the prevention of recurrence of Clostridioides difficile infection. Ferring was therefore responsible for two out of the eight biological medicine products approved by the FDA’s Center for Biologics Evaluation and Research in 2022.2

Mr. Paulsen’s appointment is one of a number of changes to the Board of Directors marking a new phase in Ferring’s growth development. Lars Rebien Sørensen, who became Executive Chairman in July 2021, will remain on the Board as Vice-Chairman. Mr. Paulsen’s father, Dr. Frederik Paulsen, who held the post of Chairman from 1988 until 2021, continues as Chairman Emeritus of the Ferring Group.

Jean-Frédéric Paulsen said: “I am honoured to take over responsibility for the Ferring Group which was founded by my grandfather Dr. Frederik Paulsen and his wife, Eva Paulsen, in 1950, and chaired by my father for more than 30 years. Under their leadership, Ferring has established a global reputation as a leader in reproductive medicine and maternal health, and in numerous specialty areas of medicine. I look forward to building on our heritage and strong foundations to lead Ferring into an exciting new era as we establish a pioneering presence in areas such as uro-oncology and the microbiome.”

Mr. Paulsen has been Chairman of Ferring Ventures SA and FinVector Oy since 2020, and previously served as Senior Advisor to four Ministers of Economy and Sustainable Development in Georgia. He began his career working at Mars Inc., Coca Cola and Credit Suisse. Mr. Paulsen gained a Master’s degree in Finance from the London School of Economics and Political Science, and is a Fellow of the Chartered Institute of Management Accountants in the UK.

In other significant changes to the Board of Directors, Viviane Monges joins the Board and has been appointed as Chair of the Audit and Finance Committee in place of Hélène Ploix, who has stood down from the Board of Directors. Ms. Monges previously held senior corporate positions in the life sciences and consumer sectors. She was a Chief Financial Officer at Wyeth Pharmaceuticals/Pfizer, Novartis and Galderma before becoming Vice-President Business Excellence Finance & Control at Nestlé.

Henrik Normann also joins Ferring’s Board of Directors, having previously been President and CEO of Nordic Investment Bank, the international financial institution of the Nordic and Baltic countries. Mr. Normann spent much of his career at Danske Bank, starting as a management trainee in 1983 and later becoming Head of Danske Bank in Denmark and Global Head of Danske Markets.

At the same time, Jeffrey Hobbs and Alexandra, Countess of Frederiksborg have stood down from the Board of Directors. All changes are effective from 1st July 2023.

Mr. Sørensen said: “As Vice-Chairman of the Board of Directors, I am pleased to support the new Executive Chairman during a period of transition as he takes on greater responsibilities from the Chairman Emeritus. I would like to welcome the new members of the Board of Directors, and to sincerely thank those who have done so much to drive the company’s long-term strategy, helping more people around the world to build families and live better lives.”

About Ferring Pharmaceuticals

Ferring Pharmaceuticals is a research-driven, specialty biopharmaceutical group committed to helping people around the world build families and live better lives. Headquartered in Saint-Prex, Switzerland, Ferring is a leader in reproductive medicine and maternal health, and in specialty areas within gastroenterology and urology. Ferring has been developing treatments for mothers and babies for over 50 years and has a portfolio covering treatments from conception to birth. Founded in 1950, privately-owned Ferring employs over 7,000 people worldwide. The company has operating subsidiaries in more than 50 countries and markets its products in over 100 countries.

Learn more at www.ferring.com, or connect with us on Twitter, Facebook, Instagram, LinkedIn and YouTube.

References

1 This refers to the Board of Directors of Ferring Holding SA, the parent company of the Ferring Pharmaceuticals group.
2 U.S. Food and Drug Administration. 2022 Biological License Application Approvals. Available at: https://www.fda.gov/vaccines-blood-biologics/development-approval-process-cber/2022-biological-license-application-approvals. Last accessed June 21, 2023.

# # #

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Bhavin Vaid
Head of Corporate Communications & Public Affairs
+41 79 191 0632 (mobile)
bhavin.vaid@ferring.com

Carine Julen
Manager, Corporate Communications & Public Affairs
+41 76 301 0178 (mobile)
carine.julen@ferring.com

About Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Brisbane Airport embraces advanced analytics from Cirium Sky Warehouse17.3.2025 23:00:00 CET | Press Release

Brisbane Airport (BNE), which serves as the major gateway to Queensland, has partnered with aviation analytics firm, Cirium, to become one of the first airports to integrate Cirium Sky Warehouse, a data-driven cloud platform, into its modernisation efforts. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250317052819/en/ Brisbane Airport Cirium’s advanced data and analytics will be seamlessly integrated with Brisbane Airport’s business systems. This integration will support enhanced capacity planning, resource allocation, and operations analysis. Jeremy Bowen, Cirium CEO, commented: "We are delighted to support Brisbane Airport’s transformative investment to revolutionise its passenger experience and meet future travel demand. “Integrating Cirium data and analytics through the Cirium Sky Warehouse will help the airport to consolidate and accelerate digitization, leading to improved decision-making and operational performance.

Trump-Inspired World Liberty Financial Closes $550 Million Across Token Sales17.3.2025 20:37:00 CET | Press Release

World Liberty Financial, Inc. (“WLFI”), the developer of a pioneering DeFi protocol and governance platform inspired by Donald J. Trump, has made history with the completion of the second set of its token sales, totaling $550 million in gross proceeds in concurrent U.S. and non-U.S. token offerings. After launching on October 15, 2024, WLFI has successfully concluded two sets of token sales in concurrent U.S. and non-U.S. offerings. In the first set, $300 million USD of WLFI tokens were sold between the offerings, and in the second set, $250 million USD of WLFI tokens were sold between the offerings. Between all the offerings, $550 million USD in WLFI tokens have been sold. More than 85,000 total participants in the token sales underwent Know Your Customer (KYC) process to determine participation eligibility. "This milestone proves that those who truly understand crypto and finance recognize what we’re building — and that WLFI is on track to supercharge DeFi as it transforms global fin

RevBio Initiates its Pivotal Clinical Trial in Europe for its Dental Implant Stabilization Product17.3.2025 20:28:00 CET | Press Release

RevBio, Inc., announced that it has received regulatory and ethics committee approvals in multiple European countries to conduct its pivotal clinical trial for its dental implant stabilization product. The successful completion of this pivotal clinical trial will result in the CE marking approval for the product, which will allow the company to begin commercial sales in Europe. As of the date of this press release, the company has already enrolled 30 of an expected 75 patients in this clinical trial. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250306978603/en/ RevBio initiates a pivotal clinical trial in Europe for its Dental Implant Stabilization product with 30 of 75 expected patient enrollments. Clinical Images courtesy of Prof. France Lambert of the University of Liege. “The results from this ongoing international multicenter study are exceeding expectations, showcasing remarkable outcomes. We are profoundly optimisti

Egle Therapeutics Receives €9.3 Million in State Funding Under the “Innovations in Biotherapies and Bioproduction” Call for Projects from France 203017.3.2025 19:00:00 CET | Press Release

Egle Therapeutics, a clinical-stage biotechnology company developing therapies targeting regulatory T cells (Tregs) for immuno-oncology and autoimmune diseases, today announced that it has secured €9.3 million in state funding under the “Innovations in Biotherapies and Bioproduction” call for projects from the France 2030 plan, managed on behalf of the French government by Bpifrance. Founded in 2020 as a spin-off from Institut Curie, Egle Therapeutics is a clinical-stage biotechnology company specializing in immunomodulation, with the ambition to develop novel approaches to the modulation of Treg activity for the treatment of cancer and autoimmune diseases. Egle Therapeutics has developed a proprietary translational platform to identify novel tumor-infiltrating Treg targets, with the aim of developing antibody-based candidate drugs to disable Treg function and restore an effective antitumor immune response. In June 2020, Egle Therapeutics entered a strategic partnership with Takeda Pha

The World Celebrates Ireland This St Patrick’s Day17.3.2025 16:19:00 CET | Press Release

People around the world revelled in all things Irish on 17th March – the annual global celebration of Irish culture, arts and heritage known as St Patrick’s Day. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250317647496/en/ In Dublin, around half a million people lined the streets of the capital for the St Patrick’s Festival parade, which this year has the theme of ‘Adventures’ – or ‘Eachtraí’ in Irish – representing the legendary adventurous Irish spirit, loved the world over. St Patrick's Day is marked all over the world by the 70 million who claim links to Ireland. Celebrating Ireland’s national colour, the defining natural green lands, the Global Greenings returned for St Patrick’s Day, with iconic international landmarks lighting up in green including Niagara Falls, the Leaning Tower of Pisa, the Empire State Building, the Sky Tower in Auckland, the Royal Liver Building in Liverpool, the Sacré-Cœur in Paris, as well a

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye